New drug combo aims to stop breast cancer return after failed chemo

NCT ID NCT03542175

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This early-stage study tested the safety of combining the drug rucaparib with standard radiation therapy in 31 women with triple-negative breast cancer who still had cancer cells after chemotherapy and surgery. The goal was to find a safe dose and see if the combination could be given without serious side effects. The results will help guide future research on whether this approach can lower the risk of cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Norwalk Hospital

    Norwalk, Connecticut, 06850, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Rucaparib (a drug) and radiation therapy

What this could lead to

If successful, this could point toward a new combination treatment to reduce the chance of breast cancer returning after standard therapy.

What could go wrong

This is a very early (Phase 1) safety trial with only 31 participants, so it's too soon to know if it works. The drug may cause side effects, and the combination may not be more effective than radiation alone.

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.